N/A N=24 Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Clinical Study to Compare 3 Multi-Layered Foam Dressings for the Management of Chronic Wounds
Chronic Wound · Venous Leg Ulcer · Diabetic Foot Ulcer
Primary: % of Participants With Equal or Better Rate of Dressing Durability — 100.0; 94.1; 69.2; 73.3 %participants — p=0.046
Phase 2 N=28 Essential Oils for Enhancing QOL in ASD
Autism Spectrum Disorder · Quality of Life · Sleep
Primary: Pediatric Quality of Life Inventory — 45.5; 56.2; 61.5; 65.3 Total Score
N/A N=8 Acute Microvascular Changes With LDL Apheresis
Hyperlipidemia
Primary: Myocardial Perfusion at Rest — 55; 135 IU/s
N/A N=37 Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy
Ureteral Injury
Primary: Quality of Ureteral Efflux Coloration With Sodium Fluorescein Collected With Dedicated Questionnaire — 23; 4; 1; 1 Participants
Phase 2 N=8 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
Morphea
Primary: Number of Participants Who Had a Reduction in Dermal Thickness of Sentinel Plaque — 5 Participants
Phase 4 N=40 Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
Bipolar Disorder
Primary: Montgomery-Asberg Depression Rating Scale — -39.24 Percent change in MADRS from baseline
Phase 2 N=166 A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
Various Advanced Cancer
Primary: Number of Safety Lead-In Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Number of participants
Phase 2 N=18 Hyperbaric Treatment of Traumatic Brain Injury (TBI)
Traumatic Brain Injury
Primary: Number of Participants With Improved Cerebral Perfusion — 8 Participants
N/A N=311 Efficacy of a Web-Based Alcohol Intervention for High School Students
Underage Drinking
Primary: Weekly Drinking — 4.14; 3.06; 2.92; 2.55 drinks per week
Phase 2 N=58 Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
Hereditary Angioedema (HAE)
Primary: Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score — 13.96; 15.04; 10.54; 18.42 VAS score - millimeters — p=0.0024
Phase 2 N=102 Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing
Fracture
Primary: Fracture Healing Will be Assessed Clinically Using Function IndeX for Trauma (FIX-IT) — 10.1; 9.7; 9.3; 9.0 scores on a scale
N/A N=200 Preoperative Cognitive Screening of Elderly Surgical Patients
Cognitive Impairment
Primary: Number of Patients With Probable Cognitive Impairment — 23; 22 Participants
Phase 3 N=813 A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)
Acne Vulgaris
Primary: Absolute Change in Mean Lesion Counts at Week 12 — -21.0; -16.4; -15.6; -12.4 lesion counts
Phase 1 N=30 Study of Copanlisib in Hepatic or Renal Impairment
Hepatic Insufficiency, Renal Insufficiency
Primary: Maximum Observed Concentration (Cmax) of Copanlisib in Plasma. — 68.12; 71.09; 31.77; 49.20 μg/L